These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34822948)

  • 21. Therapeutic strategies for diseases caused by loss-of-function mutations in G protein-coupled receptors.
    Wang W; Guo DY; Tao YX
    Prog Mol Biol Transl Sci; 2019; 161():181-210. PubMed ID: 30711027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes.
    Ahrén B
    Nat Rev Drug Discov; 2009 May; 8(5):369-85. PubMed ID: 19365392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Misfolded G Protein-Coupled Receptors and Endocrine Disease. Molecular Mechanisms and Therapeutic Prospects.
    Ulloa-Aguirre A; Zariñán T; Jardón-Valadez E
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The EP3 Receptor/G
    Schaid MD; Wisinski JA; Kimple ME
    AAPS J; 2017 Sep; 19(5):1276-1283. PubMed ID: 28584908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic Functions of G Protein-Coupled Receptors and β-Arrestin-Mediated Signaling Pathways in the Pathophysiology of Type 2 Diabetes and Obesity.
    Oliveira de Souza C; Sun X; Oh D
    Front Endocrinol (Lausanne); 2021; 12():715877. PubMed ID: 34497585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking.
    Roed SN; Nøhr AC; Wismann P; Iversen H; Bräuner-Osborne H; Knudsen SM; Waldhoer M
    J Biol Chem; 2015 Jan; 290(2):1233-43. PubMed ID: 25451942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. G protein-coupled receptors as new therapeutic targets for type 2 diabetes.
    Reimann F; Gribble FM
    Diabetologia; 2016 Feb; 59(2):229-33. PubMed ID: 26661410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current status of G-protein coupled receptors as potential targets against type 2 diabetes mellitus.
    Hoque M; Ali S; Hoda M
    Int J Biol Macromol; 2018 Oct; 118(Pt B):2237-2244. PubMed ID: 30030074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors.
    Klen J; Dolžan V
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon.
    Spezani R; Mandarim-de-Lacerda CA
    Life Sci; 2022 Jan; 288():120188. PubMed ID: 34861287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of novel ligands for peptide GPCRs.
    Moran BM; McKillop AM; O'Harte FP
    Curr Opin Pharmacol; 2016 Dec; 31():57-62. PubMed ID: 27607913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
    Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z
    Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314
    [No Abstract]   [Full Text] [Related]  

  • 34. Dysfunction of the adhesion G protein-coupled receptor latrophilin 1 (ADGRL1/LPHN1) increases the risk of obesity.
    Dietzsch AN; Al-Hasani H; Altschmied J; Bottermann K; Brendler J; Haendeler J; Horn S; Kaczmarek I; Körner A; Krause K; Landgraf K; Le Duc D; Lehmann L; Lehr S; Pick S; Ricken A; Schnorr R; Schulz A; Strnadová M; Velluva A; Zabri H; Schöneberg T; Thor D; Prömel S
    Signal Transduct Target Ther; 2024 Apr; 9(1):103. PubMed ID: 38664368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relevance of weight in the management of patients with type 2 diabetes mellitus: towards an adipocentric approach to diabetes.
    Gorgojo Martínez JJ
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():8-16. PubMed ID: 28760227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations in rhodopsin, endothelin B receptor, and CC chemokine receptor 5 in large animals: Modeling human diseases.
    Ji RL; Tao YX
    Prog Mol Biol Transl Sci; 2022; 189(1):155-178. PubMed ID: 35595348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea.
    Kim MK; Ko SH; Kim BY; Kang ES; Noh J; Kim SK; Park SO; Hur KY; Chon S; Moon MK; Kim NH; Kim SY; Rhee SY; Lee KW; Kim JH; Rhee EJ; Chun S; Yu SH; Kim DJ; Kwon HS; Park KS;
    Diabetes Metab J; 2019 Aug; 43(4):398-406. PubMed ID: 31441247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the glucagon receptor family for diabetes and obesity therapy.
    Cho YM; Merchant CE; Kieffer TJ
    Pharmacol Ther; 2012 Sep; 135(3):247-78. PubMed ID: 22659620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and preparation of the class B G protein-coupled receptors GLP-1R and GCGR for
    Wang H; Hu W; Liu D; Wüthrich K
    FEBS J; 2021 Jul; 288(13):4053-4063. PubMed ID: 33369025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. G protein-coupled receptor mutations and human genetic disease.
    Thompson MD; Hendy GN; Percy ME; Bichet DG; Cole DE
    Methods Mol Biol; 2014; 1175():153-87. PubMed ID: 25150870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.